Novartis (NVS) expanded its gene therapy collaboration with Voyager Therapeutics (VYGR) on Monday. VYGR stock rocketed above its 200-day line for the first time in four months.

prescription to succeed in the market may make your head spin. On this episode of “Industry Insights,” we’ll discuss what factors to consider with biotech stocks. We also examine how FDA approvals influence sector performance over the long term.” vid-name=”Biotech Stocks Are Shooting Higher. Here’s How You Can Play Them.” vid-cat=”Industry Insights” vid-date=”12/19/2023″ vid-date-tmsp=”1702977121″ vid-image=”https://www.investors.com/wp-content/uploads/2023/12/pXpNIwoM-640×360.jpg” vid-authors=”MEREDITH HEYMAN”>
X

The two companies will work together to test gene therapies for Huntington’s disease and spinal muscular atrophy. Both inherited disorders affect a patient’s voluntary movements.

Under the deal’s terms, Voyager will receive $100 million up front, including $20 million in equity, and up to $1.2 billion in milestone payments. Voyager is also eligible to receive tiered royalties on sales of new drugs that use its technology.

In premarket trades on today’s stock market, VYGR stock catapulted around 25% to 10.67. That pushed shares above their 200-day line, according to MarketSmith.com. Novartis stock was flat.

More to follow.

Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.

YOU MAY ALSO LIKE:

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

Why CymaBay Morphed From Dollar Stock To Biotech Rocket

Looking For The Next Big Stock Market Winners? Start With These 3 Steps

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader